Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Makoto Endo"'
Publikováno v:
Thoracic Cancer, Vol 15, Iss 22, Pp 1718-1720 (2024)
Abstract This report addresses the management strategy and effectiveness of robot‐assisted thoracoscopic surgery (RATS) for treating local recurrence of thymoma, a condition often complicated by severe adhesions and limited data on re‐operation f
Externí odkaz:
https://doaj.org/article/394621b7571e4b93ba841c4a5319c68f
Autor:
Yasuhiko Kokubu, Toshifumi Fujiwara, Koh Nakagawa, Nokitaka Setsu, Makoto Endo, Jun‐Ichi Fukushi, Yoshihiro Matsumoto, Yasuharu Nakashima
Publikováno v:
Journal of Foot and Ankle Research, Vol 15, Iss 1, Pp n/a-n/a (2022)
Abstract Background Tumors and tumor‐like lesions of the foot and ankle are relatively rare and their postoperative clinical outcome has not been well reported. Methods This study retrospectively reviewed medical records of all patients who underwe
Externí odkaz:
https://doaj.org/article/4550eddf02f3486683c006b5cd7f4c7a
Autor:
Makoto Endo, Shunji Takahashi, Nobuhito Araki, Hideshi Sugiura, Takafumi Ueda, Tsukasa Yonemoto, Mitsuru Takahashi, Hideo Morioka, Hiroaki Hiraga, Toru Hiruma, Toshiyuki Kunisada, Akihiko Matsumine, Kazato Goda, Akira Kawai
Publikováno v:
Cancer Medicine, Vol 9, Iss 11, Pp 3656-3667 (2020)
Abstract The time course of the response to each drug is important to avoid inappropriate termination of treatment by misjudging tumor progression; however, little is known about soft tissue sarcoma (STS) regarding this matter. This study aimed to pe
Externí odkaz:
https://doaj.org/article/72f22d66938e4509814e74c406f73671
Class III β-Tubulin Overexpression Induces Chemoresistance to Eribulin in a Leiomyosarcoma Cell Line
Autor:
Kenichiro Yahiro, Yoshihiro Matsumoto, Jun-ichi Fukushi, Ken-ichi Kawaguchi, Makoto Endo, Nokitaka Setsu, Keiichiro IIda, Suguru Fukushima, Makoto Nakagawa, Atsushi Kimura, Yoshinao Oda, Yasuharu Nakashima
Publikováno v:
Analytical Cellular Pathology, Vol 2018 (2018)
Eribulin is a new drug to treat soft tissue sarcoma (STS) that exerts antitumor activity by binding to microtubules. The prognosis of STS is poor, and eribulin is expected to improve the treatment outcome. We observed several cases that exhibited res
Externí odkaz:
https://doaj.org/article/685608d714b54d85867409d5e1b41ca1
Autor:
Mikiya Ishihara, Yoshihiro Nishida, Shigehisa Kitano, Akira Kawai, Daisuke Muraoka, Fumiyasu Momose, Naozumi Harada, Yoshihiro Miyahara, Naohiro Seo, Hiroyoshi Hattori, Kohichi Takada, Makoto Emori, Shigeki Kakunaga, Makoto Endo, Yoshihiro Matsumoto, Tetsuro Sasada, Eiichi Sato, Tomomi Yamada, Akihiko Matsumine, Yasuhiro Nagata, Takashi Watanabe, Shinichi Kageyama, Hiroshi Shiku
Publikováno v:
International Journal of Cancer. 152:2554-2566
Autor:
Hiroaki Hiraga, Makoto Endo, Takafumi Ueda, Akihiko Matsumine, Toru Hiruma, Nobuhito Araki, Hideo Morioka, Tsukasa Yonemoto, Toshiyuki Kunisada, Kazato Goda, Shunji Takahashi, Akira Kawai, Hideshi Sugiura, Mitsuru Takahashi
Publikováno v:
Cancer Medicine, Vol 9, Iss 11, Pp 3656-3667 (2020)
Cancer Medicine
Cancer Medicine
The time course of the response to each drug is important to avoid inappropriate termination of treatment by misjudging tumor progression; however, little is known about soft tissue sarcoma (STS) regarding this matter. This study aimed to perform a t
Autor:
Makoto Endo, Hiroaki Hiraga, Takafumi Ueda, Robert Nakayama, Naomasa Fukase, Eisuke Kobayashi, Masato Tomita, Akira Kawai, Tomoaki Mori, Hideo Morioka
Publikováno v:
Journal of Surgical Oncology. 114:495-500
Background Leiomyosarcoma of bone (LMSoB) is a rare malignant bone tumor. This multicenter retrospective study was conducted to investigate the diagnosis and the clinical outcome of primary LMSoB in Japan. Methods Forty-eight patients (average age: 5
Autor:
Shoji Tokunaga, Makoto Endo, Kenichi Kohashi, Yoshinao Oda, Yuichi Yamada, Fumiyoshi Fushimi, Yukihide Iwamoto, Hidetaka Yamamoto, Yusuke Takahashi, Nokitaka Setsu
Publikováno v:
Cancer. 120:864-876
BACKGROUND Solitary fibrous tumors (SFTs) are soft tissue tumors of intermediate malignancy that rarely metastasize. Although unresectable SFTs are reported to have a poor prognosis, to the authors' knowledge there is currently no effective therapy.
Autor:
Koichirou Yokoyama, Nokitaka Setsu, Yusuke Takahashi, Makoto Endo, Kenichi Kohashi, Fumiyoshi Fushimi, Yukihide Iwamoto, Takeaki Ishii, Yuichi Yamada, Hidetaka Yamamoto, Yoshinao Oda
Publikováno v:
Cancer. 119:3504-3513
BACKGROUND The Akt/mammalian target of rapamycin (mTOR) pathway, downstream from phosphatidylinositol 3-kinase (PI3K), mediates cell survival and proliferation. Although this pathway reportedly contributes to the progression of synovial sarcoma, its
Autor:
Nokitaka Setsu, Yusuke Takahashi, Takeaki Ishii, Hidetaka Yamamoto, Yukihide Iwamoto, Yoshinao Oda, Makoto Endo, Shuichi Matsuda
Publikováno v:
Pathology International. 63:226-229
Fibrocartilaginous mesenchymoma (FCM) of the bone is a rare tumor, with only 21 reported cases since 1984. It usually occurs in the long bones of children and adolescents, but in this case, the tumor arose in the pubic bone. The pathological diagnosi